Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in
children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS)
and to assess clinical response associated with this treatment as well as overall survival.